 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Consumer Drug Information |
| Routes of administration | Injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.067.337 |
| Chemical and physical data | |
| Formula | C17H17N7O8S4 |
| Molar mass | 575.60 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Cefotetan is an injectableantibiotic of thecephamycin type for prophylaxis and treatment ofbacterial infections. It is often grouped together with second-generationcephalosporins and has a similar antibacterial spectrum, but with additional anti-anaerobe coverage.
Cefotetan was developed byYamanouchi. It is marketed outside Japan byAstraZeneca with the brand namesApatef andCefotan.
The chemical structure of cefotetan, like that of several other cephalosporins, contains anN-methylthiotetrazole (NMTT or 1-MTT)side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can causehypoprothrombinemia (likely due toinhibition of theenzymevitamin K epoxide reductase) and a reaction with ethanol similar to that produced bydisulfiram (Antabuse), due to inhibition ofaldehyde dehydrogenase.[1]
Cefotetan has a broad spectrum of activity and has been used to treat bacterial infections of the bone, skin, urinary tract, and lower respiratory tract. Notable species includeBacteroides, Streptococcus, andEscherichia. The following represents MIC susceptibility data for a few medically significant bacteria.[2]